News

Professor Park Jung-je of the Department of Otolaryngology and Otolaryngology at Gyeongsang National University Hospital ...
The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.